“Unhappy” BMS To ImClone: Erbitux, Follow-on Still Ours

After the rejected buyout offer, rights to compounds won't be modified.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet